- Conditions
- Bipolar Disorder
- Interventions
- Bupropion, Placebo
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2761–2784
of 17,854
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Melanoma
- Interventions
- VCL-IM01 (encoding IL-2) with Electroporation
- Genetic
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
- Conditions
- Malaria
- Interventions
- BNT165c, BNT165d, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
- Conditions
- Acute Schizophrenia
- Interventions
- OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Glendale, California + 12 more
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- Itacitinib, Placebo, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 39
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
- Conditions
- Fanconi Anemia
- Interventions
- JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab
- Drug · Device · Biological
- Lead sponsor
- Porteus, Matthew, MD
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma
- Interventions
- Dordaviprone (ONC201)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Epilepsy, Alzheimer Disease, Epilepsy Intractable
- Interventions
- NPT 2042 (bumetanide analog) or Matching Placebo
- Drug
- Lead sponsor
- NeuroPro Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Technetium-99m macroaggregated albumin (Tc-99m MAA)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 6 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Cancer
- Interventions
- Medpulser Electroporation with Bleomycin
- Combination Product
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Breast Cancer, Breast Cancer Surgery
- Interventions
- Positron Emission Mammography (PEM)
- Device
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Interventions
- α-lactalbumin vaccine, Zymosan
- Biological
- Lead sponsor
- George T. Budd
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Hydroxychloroquine, Bevacizumab
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Hamilton, New Jersey • New Brunswick, New Jersey
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Interventions
- Brexpiprazole, OPC-34712
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 28
- States / cities
- Imperial, California • Lakewood, California • Long Beach, California + 21 more
- Conditions
- Diabetes
- Interventions
- Mixed Meal Test, Dual Energy X-Ray Absorptiometry (DEXA), Adipose Tissue Biopsy
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Healthy
- Interventions
- ATX-101
- Drug
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Effects of Chemotherapy
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 20 Years to 50 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hyperphagia in Prader-Willi Syndrome
- Interventions
- FE 992097, Placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Mineola, New York • Nashville, Tennessee
- Conditions
- Renal Cell Carcinoma
- Interventions
- BMS-936558 (Anti-PD-1)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 12
- States / cities
- San Francisco, California • New Haven, Connecticut • Tampa, Florida + 8 more
- Conditions
- Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Hematologic Malignancies
- Interventions
- Pegfilgrastim
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Pancreatic Cancer
- Interventions
- Capecitabine, Docetaxel, Gemcitabine
- Drug
- Lead sponsor
- Tony Bekaii-Saab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Columbus, Ohio
- Conditions
- Healthy Volunteer
- Interventions
- Placebo, RO4917838, diazepam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah